FibroGen (FGEN) Misses Q3 EPS by 15c

FibroGen (NASDAQ: FGEN) reported Q3 EPS of ($0.50), $0.15 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $29.03 million versus the consensus estimate of $36.48 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c